Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms whose incidence has increased significantly in recent years, and whose optimal management remains controversial. We report the latest innovations in their management, in particular the results of three trials concerning the use of the mammalian target of rapamycin (mTOR) inhibitor, everolimus, in non-functional NETs of lung/ gastrointestinal (GI) origin, the first randomised trial of radiolabelled 177 Lu-DOTATATE in patients with mid-gut NETs, and the use of the 5-HT synthesis inhibitor, telotristat etiprate, in patients with the carcinoid syndrome.
Neuroendocrine tumours (NETs) represent a heterogeneous group of neoplasms that originate from different types of neuroendocrine cells throughout the body. 1 While previously considered to be relatively uncommon, their overall incidence has been reported as increasing for reasons which are unclear. [2] [3] [4] Surgery is the only truly curative therapy, but there are now a variety of other treatment options although their specific use and sequencing remains controversial. 3 However, somatostatin analogues (SSAs), particularly the long-acting formulations of octreotide and lanreotide, are highly effective for symptomatic patients with secretory syndromes, and recent studies have also shown their ability to retard tumour progression in the PROMID, CLARINET and RADIANT-2 trials. [5] [6] [7] [8] The multi-ligand SSA pasireotide was also shown to control the symptoms of carcinoid syndrome in patients with advanced
NETs refractory/resistant to octreotide long-acting release (LAR) therapy. Previous studies have demonstrated the efficacy of everolimus, an inhibitor of mammalian target of rapamycin (mTOR) (a serine-threonine kinase that stimulates cell growth, proliferation and angiogenesis) [10] [11] [12] to slow tumour progression of pancreatic NETs (RADIANT-3) 13 and symptomatic mid-gut tumours (RADIANT-2).
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RADIANT-4 was a placebo-controlled, double-blind, phase III study carried out in 13
European centres on the efficacy and safety of everolimus in patients with advanced, progressive, non-functional NETs of the lung and gut. In current practice, patients with CS are generally treated with longacting SSAs which have an inhibitory effect on tumour secretion of serotonin and other neuropeptides into the systemic circulation. 
